about
Redistribution of DAT/α-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's diseaseReciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerizationGlutamatergic neurons induce expression of functional glutamatergic synapses in primary myotubesNF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 productionThe neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexesOpposing roles for NF-kappa B/Rel factors p65 and c-Rel in the modulation of neuron survival elicited by glutamate and interleukin-1betaGroup-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection.Glutamatergic reinnervation through peripheral nerve graft dictates assembly of glutamatergic synapses at rat skeletal muscle.SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's diseaseGene expression profile activated by the chemokine CCL5/RANTES in human neuronal cells.Evidence for the presence of alpha1 adrenoceptor subtypes in the human ureter.Pharmacological basis for dopamine D-2 receptor diversity.Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First?NF-κB in Innate Neuroprotection and Age-Related Neurodegenerative Diseases.An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomasLate-onset Parkinsonism in NFκB/c-Rel-deficient miceThe NMDA/D1 receptor complex as a new target in drug development.Glutamatergic innervation of rat skeletal muscle by supraspinal neurons: a new paradigm in spinal cord injury repair.Distinct roles of diverse nuclear factor-kappaB complexes in neuropathological mechanisms.Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.Post-ischemic brain damage: NF-kappaB dimer heterogeneity as a molecular determinant of neuron vulnerability.NF-kappaB dimers in the regulation of neuronal survival.Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function.Nerve growth factor in the anterior pituitary: localization in mammotroph cells and cosecretion with prolactin by a dopamine-regulated mechanism.Nerve growth factor signaling in prostate health and disease.From α-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease.NF-κB and epigenetic mechanisms as integrative regulators of brain resilience to anoxic stress.Structural plasticity in mesencephalic dopaminergic neurons produced by drugs of abuse: critical role of BDNF and dopamine.The "in situ" proximity ligation assay to probe protein-protein interactions in intact tissues.Deafferentation induces early and delayed differential changes in the pattern of expression of the various guanine nucleotide binding protein mRNAs in rat striatum.Interleukin-1beta and glutamate activate the NF-kappaB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures.Leptin is induced in the ischemic cerebral cortex and exerts neuroprotection through NF-kappaB/c-Rel-dependent transcription.Review: Parkinson's disease: from synaptic loss to connectome dysfunction.The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines.Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure.GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity.Muscarinic receptors stimulate cell proliferation in the human urothelium-derived cell line UROtsa.Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease.Effects of olanzapine on glucose transport, proliferation and survival in C2C12 myoblasts.
P50
Q24299645-EEAF3ECF-E535-48D3-A0AD-0242FABD9D3CQ24323514-9342F385-6FD3-4B8D-87EE-58E939BD2451Q27308992-11852FB3-7894-4059-8616-617CAED3A1C5Q28196676-F44986DC-0E89-40EF-8359-B7A2E5D69162Q28289714-789C9AFD-EB62-487E-9DF4-0A028084F9C7Q28581717-22449BB6-4A4E-4748-B23E-EECE26B05AC2Q33756939-E99DEF5B-346A-4012-9299-0D2A2E4D5D54Q33841591-20D09B96-A419-4CBF-B06E-25211471DDB5Q33944220-E5E7DD56-53DB-40AD-ABBC-9DE9EBACFD78Q33981681-69BA34DB-1300-44C1-9AED-06078A1E867AQ34390786-0EC60C01-DA9C-4C88-ADE2-B86794A42716Q35282071-A653FEFC-62C4-48FC-AFBF-28FAE6294A70Q35412397-4285F0D0-A9ED-42FA-A870-9B20A0ECFDE8Q35627153-E1568A2D-E822-4B24-9FB1-22065A4A1F65Q35762997-152726F0-38D2-4714-BD02-60FDC1F81046Q36081822-4CE4B4DA-D50F-401A-AC2D-24C4DA4201DAQ36218699-11BEFE00-D75E-43F6-A8DE-A27A24C6A2D7Q36486262-265EC654-C8F1-4E4E-A2AD-1F279C8B7713Q36488468-3ED3947F-8A2B-44AC-BCDA-23C3CDB9C685Q36541046-3E832269-072D-4AEA-A6B7-A0EC8FDBE33EQ37220785-BF17218A-46EC-49FE-B73F-A530FDB13CFDQ37352183-4C513D2F-C4AC-46BA-96B4-0459052AF5DBQ37553228-95C25F1A-FE56-4097-AD57-18E99E482514Q37616896-3F14E492-F3E7-4B90-9E58-771B9B20B175Q37634036-A8C73824-2EB2-483A-9946-91BC3C7BE05BQ37694590-F83E744E-30A0-446A-BD27-03AD69A7E2BDQ38007671-A4288755-28CB-4DDC-A065-8B6AAB7A6996Q38009157-9E9D3498-C0EF-442D-BA51-1F06358B733DQ38287920-F584720C-FDBA-4B1B-A4E8-65617FEEFC5CQ38306271-0A65DF5F-5E70-4425-8776-2BB0DD2F1E6DQ38313283-1D353F60-DEC3-4C7B-89DD-AB0B28F032BCQ38356337-2BC573CA-9A24-4C3F-B06F-9C0621D91192Q38358764-B08A8122-2A77-434B-92CE-83106500D9C3Q38650395-315B2D4C-56EC-4FA1-B6EF-46D253B091A7Q38791765-31E50D88-5D95-4FE9-935E-AD06CABF99EDQ38890512-1F75916D-651F-4E2E-9559-1CCF556CD43CQ39019030-565BD5FC-3AF2-4CF1-A9C9-DE9EE883D20BQ39515235-B1BFF6C7-4613-4791-937B-0B96DAEFF407Q39618931-52774C3B-2450-4E14-98A4-A68650966D24Q39976797-6F87EADF-BFC9-48A3-A439-2C0DCDAC4B64
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
PierFranco Spano
@ast
PierFranco Spano
@en
PierFranco Spano
@es
PierFranco Spano
@nl
type
label
PierFranco Spano
@ast
PierFranco Spano
@en
PierFranco Spano
@es
PierFranco Spano
@nl
altLabel
PIERFRANCO SPANO
@en
Pierfranco Spano
@en
Spano P
@en
prefLabel
PierFranco Spano
@ast
PierFranco Spano
@en
PierFranco Spano
@es
PierFranco Spano
@nl
P1053
J-9944-2016
P106
P1153
55431614400
P31
P4012
P496
0000-0002-9906-0964